High nontransferrin bound iron levels and heart disease in thalassemia major

American Journal of Hematology

Volumn 84, Issue 1, 2009, Pages 29-33

  Piga, Antonio ^a,e   Longo, Fiomena ^a   Duca, Lorena ^b   Roggero, Simona ^a   Vinciguerra, Tiziana ^a   Calabrese, Roberto ^c   Hershko, Chaim ^d   Cappellini, Maria Domenica ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^e Dipartimento di Scienze Cliniche e Biologiche   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FERRITIN; IRON; TRANSFERRIN;

ADULT; ARTICLE; BLOOD TRANSFUSION; CHELATION; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; FERRITIN BLOOD LEVEL; HEART DISEASE; HUMAN; HYPOTHESIS; IRON BLOOD LEVEL; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; ARRHYTHMIAS, CARDIAC; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FERRITINS; HUMANS; HYPERTENSION, PULMONARY; IRON; IRON OVERLOAD; MALE; MIDDLE AGED; REGRESSION ANALYSIS; THALASSEMIA; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 58149458142     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21317     Document Type: Article

References (39)

1. Andrews N. Disorders of iron metabolism. N Engl J Med 1999:341:1986-1995.
2. Hershko C. Iron loading and its clinical implications. Am J Hematol 2007;82:1147-1148.
3. Hershko C, Graham G, Bates G, Rachmilewitz E. Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity. Br J Haematol 1978:40:255-263.
4. Le Lan C, Loreal O, Cohen T, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005:105:4527-4531.
5. Cortelezzi A, Cattaneo C, Cristiani S, et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J 2000;1:153-158.
6. Gafter-Gvili A. Prokocimer M. Breuer W. et al. Non-transferrin-bound serum iron (NTBI) in megaloblastic anemia: Effect of vitamin B(12) treatment. Hematol J 2004:5:32-34.
7. Bradley SJ, Gosriwitana I, Srichairatanakool S, et al. Non-transferrin-bound iron induced by myeloablative chemotherapy. Br J Haematol 1997;99:337-343.
8. Durken M, Nielsen P, Knobel S, et al. Nontransferrin-bound iron in serum of patients receiving bone marrow transplants. Free Radic Biol Med 1997;22: 1159-1163.
9. Durken M, Herrnring C, Finckh B, et al. Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Radic Biol Med. 2000:28:887-894.
10. Sahlstedt L, Ebeling F von Bonsdorff L, et al. Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol 2001;113:836-838.
11. Sahlstedt L, von Bonsdorff L, Ebeling F, et al. Effective binding of free iron by a single intravenous dose of human apotransferrin in haematological stem cell transplant patients. Br J Haematol 2002; 119:547-553.
12. Pootrakul P, Breuer W, Sametband M, et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004;104:1504-1510.
13. Breuer W, Ermers M, Pootrakul P, et al. Desferrioxamine-chelatable iron (DO), a component of serum non-fransferrin-bound iron (NTBI) used for assessing iron chelation therapy. Transfus Sci 2000;23:241-242.
14. Esposito BR Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood 2003; 102:2670-2677.
15. Liu Y, Parkes JG, Templeton DM. Differential accumulation of non-transferrinbound iron by cardiac myocytes and fibroblasts. J Mol Cell Cardiol 2003; 35:505-514,
16. Link G, Saada A, Pinson A, et al. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J Lab Clin Med 1998;131:466-474.
17. Chua AC, Olynyk JK, Leedman PJ, Trinder D. Nontransferrin-bound iron uptake by hepatocytes is increased in the Hfe knockout mouse model of hereditary hemochromatosis. Blood 2004;104:1519-1525.
18. Link G, Pinson A, Hershko C. Heart cells in culture: A model of myocardial iron overload and chelation. J Lab Clin Med 1985; 106:147-153.
19. Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol 2007;82:1128-1131.
20. Jacobs EM, Hendriks JC, van Tits BL, et al. Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Anal Biochem 2005; 341:241-250,
21. Porter JB, Abeysinghe R, Marshall L, et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996;88:705-713,
22. Porter JB. Concept and goals in the management of transfusional iron overload. Am J Hematoi 2007;82:1136-1139.
23. Finch C, Deubelbeiss K, Cook J, et al. Ferrokinetics in man. Medicine (Baltimore) 1970:49:17-53.
24. Anuwatanakuichai M, Pootrakul P, Thuvasethakul P, Wasi P. Non-transferrin plasma iron in beta-thalassaemia/Hb E and haemoglobin H diseases, Scand J Haematol 1984;32; 153-158.
25. Evans RW, Rafique R, Zarea A, et al. Nature of non-transferrin-bound iron: Studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem 2008;13:57-74.
26. Jensen R Jensen F, Christensen T, et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: Indication of dose relation between myocardial iron content and chelatable iron pool. Blood 2003;101:4632-4639.
27. Jensen P, Jensen F, Christensen T, et al. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: A study in adult patients with acquired anemias. Blood 2003;101:91-96.
28. Link G, Pinson A, Hershko C. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood 1994;83:2692-2697.
29. Moreb J, Hershko C, Hasin Y. Effects of acute iron loading on contractility and spontaneous beating rate of cultured rat myocardial cells. Basic Res Cardiol 1988;83:360-368.
30. Link G, Athias P, Grynberg A, et al. Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture. J Lab Clin Med 1989;113:103-111.
31. Randell EW, Parkes JG, Olivieri NF, Templeton DM. Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J Biol Chem 1994;269:16046-16053.
32. Brittenham G, Griffith R Nienhuis A, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.
33. Hershko C, Weatherall D. Iron-chelating therapy. Crit Rev Clin Lab Sci 1988;26:303-345.
34. Aruoma O, Bomford A, Poison R, Halliwell B. Nontransferrin-bound iron in plasma from hemochromatosis patients: effect of phlebotomy therapy. Blood 1988;72:1416-1419.
35. Gosriwatana I, Loreal O, Lu S, et al. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 1999;273:212-220.
36. Beilby J, Oiynyk J, Ching S, et al. Transferrin index: An alternative method for calculating the iron saturation of transferrin. Clin Chem 1992;38:2078-2081,
37. Kasvosve I, Delanghe J. Total iron binding capacity and transferrin concentration in the assessment of iron status. Clin Chem Lab Med 2002;40:1014-1018.
38. Fischer R. Liver iron susceptometry. in: Magnetism in Medicine, A Handbook. Andrae W, Nowak H, editors. Berlin: Wiley-VCH; 1998.
39. Roper-Bouchet M, Turlin B, Graham G, et al. Drying methods affect the wetdry weight ratio of liver tissue samples and impact liver iron content (LIC) measurements. Biolron 2005;107:Abstract P274.